Abstract

BackgroundGene silencing using siRNA can be a new potent strategy to treat many incurable diseases at the genetic level, including cancer and viral infections. Treatments using siRNA essentially requires an efficient and safe method of delivering siRNA into cells while maintaining its stability. Thus, we designed novel synergistic fusion peptides, i.e., SPACE and oligoarginine.ResultsAmong the novel fusion peptides and siRNAs, nanocomplexes have enhanced cellular uptake and gene silencing effect in vitro and improved retention and gene silencing effects of siRNAs in vivo. Oligoarginine could attract siRNAs electrostatically to form stable and self-assembled nanocomplexes, and the SPACE peptide could interact with the cellular membrane via hydrogen bonding. Therefore, nanocomplexes using fusion peptides showed improved and evident cellular uptake and gene silencing of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) via the lipid raft-mediated endocytosis pathway, especially to the HDFn cells of the skin, and all of the fusion peptides were biocompatible. Also, intratumorally injected nanocomplexes had increased retention time of siRNAs at the site of the tumor. Finally, nanocomplexes demonstrated significant in vivo gene silencing effect without overt tissue damage and immune cell infiltration.ConclusionsThe new nanocomplex strategy could become a safe and efficient platform for the delivery of siRNAs into cells and tissues to treat various target diseases through gene silencing.

Highlights

  • Gene silencing using short-interfering RNA (siRNA) can be a new potent strategy to treat many incurable diseases at the genetic level, including cancer and viral infections

  • All of the nanocomplexes enhanced the cellular uptake of siRNAs such that it was similar to or better than commercialized LipofectamineTM 2000

  • Nanocomplex-mediated siRNA delivery enhanced in vivo gene silencing effect than naked siRNA delivery

Read more

Summary

Introduction

Gene silencing using siRNA can be a new potent strategy to treat many incurable diseases at the genetic level, including cancer and viral infections. As an RNAi mediator, short-interfering RNA (siRNA) is a double-stranded molecule that is composed of about 21–23 nucleotides, and it is designed as a sequence complementary to the target mRNA. The exogenously penetrated siRNAs activate the RNA-induced silencing complexes (RISC) in the cytoplasm and result in selective mRNA inhibition with low cytotoxicity. Gene silencing using siRNA can be a new potent strategy to treat cancer, viral infectious diseases, and local diseases at the genetic level. A significant barrier to siRNA delivery is that its hydrophilic nature results in low uptake efficiency into the cell membranes that are composed of phospholipid bilayers [4, 5]. It is essential to develop an efficient, safe, and stable method of delivering siRNA

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call